Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma

NCT02345408 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02345408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02345408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2015
Completion date
May 6, 2020
Enrollment
54 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer